5-NZ

We Innovate Healthcare

At Roche we focus on developing medicines and diagnostics that will help patients live longer, better lives - from early detection and prevention of disease, to diagnosis, treatment and treatment monitoring.

We strive to address unmet medical needs through excellence in science and research. Roche's personalised healthcare approach uses new molecular insights to better tailor medicines and diagnostics to patients needs. With our combined strengths in pharmaceuticals and diagnostics, no company is better suited to this task.

www.roche.com
Personalized Healthcare


2 Oct 2012

Roche Products (New Zealand) Limited welcomes the results of two studies, PHARE and HERA, which explore different treatment durations of Herceptin when used together with chemotherapy in early-stage HER2-positive breast cancer. Read More
 
6 Mar 2012

Zelboraf has received New Zealand registration from Medsafe for the treatment of people with late stage melanoma that has spread to other parts of the body and cannot be removed by surgery, where the melanoma has a mutation in the BRAF gene.Read More

 
19 Jan 2011

A partnership between the University of Auckland Business School and pharmaceutical company Roche is providing the opportunity for an Economics graduate to gain real world experience of the corporate world, whilst applying economics research techniques in a health policy setting.  Read More

 
19 Jan 2011

The Wellington Regional Rheumatology Trust has organised a summer studentship through sponsorship by pharmaceutical company Roche.  Read More

 
03 Sep 2010

New Zealanders fighting the country’s leading cause of cancer death will benefit following PHARMAC’s announcement today of their decision to fund Roche’s Tarceva® (erlotinib), a treatment that extends survival and improves quality of life for advanced lung cancer sufferers Read More



17 Jun 2009

New Zealanders diagnosed with indolent (low grade) non Hodgkin’s lymphoma (NHL) now have expanded funding for a cutting edge biotherapy, MabThera® (rituximab), increasing their chances of beating this slowly progressing but often fatal disease. Read More

 
19 May 2009

Widened access to a leading-edge biotherapy has given hope to hundreds of New Zealanders diagnosed with chronic lymphocytic leukaemia (CLL), a stubbornly incurable form of white blood cell cancer. Read More
2 Oct 2012

Roche Products (New Zealand) Limited welcomes the results of two studies, PHARE and HERA, which explore different treatment durations of Herceptin when used together with chemotherapy in early-stage HER2-positive breast cancer. Read More
 
6 Mar 2012

Zelboraf has received New Zealand registration from Medsafe for the treatment of people with late stage melanoma that has spread to other parts of the body and cannot be removed by surgery, where the melanoma has a mutation in the BRAF gene.Read More

 
19 Jan 2011

A partnership between the University of Auckland Business School and pharmaceutical company Roche is providing the opportunity for an Economics graduate to gain real world experience of the corporate world, whilst applying economics research techniques in a health policy setting.  Read More

 
19 Jan 2011

The Wellington Regional Rheumatology Trust has organised a summer studentship through sponsorship by pharmaceutical company Roche.  Read More

 
03 Sep 2010

New Zealanders fighting the country’s leading cause of cancer death will benefit following PHARMAC’s announcement today of their decision to fund Roche’s Tarceva® (erlotinib), a treatment that extends survival and improves quality of life for advanced lung cancer sufferers Read More



17 Jun 2009

New Zealanders diagnosed with indolent (low grade) non Hodgkin’s lymphoma (NHL) now have expanded funding for a cutting edge biotherapy, MabThera® (rituximab), increasing their chances of beating this slowly progressing but often fatal disease. Read More

 
19 May 2009

Widened access to a leading-edge biotherapy has given hope to hundreds of New Zealanders diagnosed with chronic lymphocytic leukaemia (CLL), a stubbornly incurable form of white blood cell cancer. Read More
2 Oct 2012

Roche Products (New Zealand) Limited welcomes the results of two studies, PHARE and HERA, which explore different treatment durations of Herceptin when used together with chemotherapy in early-stage HER2-positive breast cancer. Read More
 
6 Mar 2012

Zelboraf has received New Zealand registration from Medsafe for the treatment of people with late stage melanoma that has spread to other parts of the body and cannot be removed by surgery, where the melanoma has a mutation in the BRAF gene.Read More

 
19 Jan 2011

A partnership between the University of Auckland Business School and pharmaceutical company Roche is providing the opportunity for an Economics graduate to gain real world experience of the corporate world, whilst applying economics research techniques in a health policy setting.  Read More

 
19 Jan 2011

The Wellington Regional Rheumatology Trust has organised a summer studentship through sponsorship by pharmaceutical company Roche.  Read More

 
03 Sep 2010

New Zealanders fighting the country’s leading cause of cancer death will benefit following PHARMAC’s announcement today of their decision to fund Roche’s Tarceva® (erlotinib), a treatment that extends survival and improves quality of life for advanced lung cancer sufferers Read More



17 Jun 2009

New Zealanders diagnosed with indolent (low grade) non Hodgkin’s lymphoma (NHL) now have expanded funding for a cutting edge biotherapy, MabThera® (rituximab), increasing their chances of beating this slowly progressing but often fatal disease. Read More

 
19 May 2009

Widened access to a leading-edge biotherapy has given hope to hundreds of New Zealanders diagnosed with chronic lymphocytic leukaemia (CLL), a stubbornly incurable form of white blood cell cancer. Read More
0007507_crystalball

Diagnostics

Roche Diagnostics is the market leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management.

If you have had a sample taken for a lab test in NZ it is more than likely that the results you received were obtained on a Roche system.

Roche Diagnostics is based in Mt Wellington, Auckland. We provide innovative life science and diagnostics solutions that offer clear medical value and increase testing efficiency to improve healthcare for all New Zealanders.

Roche Diagnostics is active in all market segments, from scientific research and clinical laboratory systems to patient self-monitoring.

Diagnostics

lowres9577cobas8000

Pharmaceuticals

Roche Products is the pharmaceutical division of Roche in New Zealand.  Based in Newmarket, Auckland, we employ 60 staff in the areas of clinical research, medical information, product distribution, sales and marketing. 

Roche is the leading provider of oncology medicines in New Zealand as well as providing innovative medicines in the treatment of renal anaemia, hepatitis and rheumatoid arthritis.

Our Medicines

 

0007511